نتایج جستجو برای: refractory nhl lymphoma

تعداد نتایج: 155852  

2014
XUEDE LIN XI SHI WUCHA ZENG MIN ZHENG LIMING HUANG

The treatment of refractory or relapsed aggressive non-Hodgkin's lymphoma (NHL) in patients in a state of poor health is difficult due to their ineligibility to receive intensive salvage chemotherapy. In the present study, 16 refractory or relapsed aggressive NHL patients with a poor performance status or comorbidities were treated with mitoxantrone, etoposide, bleomycin and dexamethasone (MEBD...

Journal: :Ai zheng = Aizheng = Chinese journal of cancer 2008
Yun Fan Zhi-Yu Huang Lu-Hong Luo Hai-Feng Yu

BACKGROUND & OBJECTIVE The prognosis of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) after front-line therapy remains poor. The development of more effective and less toxic salvage regimens remains a major challenge. Gemcitabine is effective in treating lymphoma and, when combined with cisplatin, is effective for some solid tumors. This study was to evaluate the efficacy of GD...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016
Maria-Elisabeth Goebeler Stefan Knop Andreas Viardot Peter Kufer Max S Topp Hermann Einsele Richard Noppeney Georg Hess Stefan Kallert Andreas Mackensen Kathrin Rupertus Lothar Kanz Martin Libicher Dirk Nagorsen Gerhard Zugmaier Matthias Klinger Andreas Wolf Brigitte Dorsch Beate D Quednau Margit Schmidt Jürgen Scheele Patrick A Baeuerle Eugen Leo Ralf C Bargou

PURPOSE Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the treatment of Philadelphia chromosome-negative acute B-lymphoblastic leukemia. We evaluated blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). PATIENTS AND METHODS This 3 + 3 design, phase I dose-escalation study determined adverse events and the maximum tolerated dose (MTD) of co...

2014
Corrado Tarella Angela Gueli Federica Delaini Andrea Rossi Anna Maria Barbui Giuseppe Gritti Cristina Boschini Daniele Caracciolo Riccardo Bruna Marco Ruella Daniela Gottardi Roberto Passera Alessandro Rambaldi Francesco Bertolini

BACKGROUND Primary refractory disease is a main challenge in the management of non-Hodgkin's Lymphoma (NHL). This survey was performed to define the rate of refractory disease to first-line therapy in B and T-cell NHL subtypes and the long-term survival of primary refractory compared to primary responsive patients. METHODS Medical records were reviewed of 3,106 patients who had undergone prim...

2013
Katia Beider Elena Ribakovsky Michal Abraham Hanna Wald Lola Weiss Evgenia Rosenberg Eithan Galun Abraham Avigdor Orly Eizenberg Amnon Peled Arnon Nagler

Purpose:Chemokine axis CXCR4/CXCL12 is critically involved in the survival and trafficking of normal andmalignant B lymphocytes.Here,we investigated the effect of high-affinityCXCR4antagonist BKT140on lymphoma cell growth and rituximab-induced cytotoxicity in vitro and in vivo. Experimental Design: In vitro efficacy of BKT140 alone or in combination with rituximab was determined in non-Hodgkin ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2013
Katia Beider Elena Ribakovsky Michal Abraham Hanna Wald Lola Weiss Evgenia Rosenberg Eithan Galun Abraham Avigdor Orly Eizenberg Amnon Peled Arnon Nagler

PURPOSE Chemokine axis CXCR4/CXCL12 is critically involved in the survival and trafficking of normal and malignant B lymphocytes. Here, we investigated the effect of high-affinity CXCR4 antagonist BKT140 on lymphoma cell growth and rituximab-induced cytotoxicity in vitro and in vivo. EXPERIMENTAL DESIGN In vitro efficacy of BKT140 alone or in combination with rituximab was determined in non-H...

Journal: :medical journal of islamic republic of iran 0
noor-i-kiran naeem 9-r, jasmine lane, faisal ghuman shaheed road, lahore cantt, pakistan.سازمان اصلی تایید شده: 0 موسسات و مراکز خارج از کشور farhatulain ahmed 32-b,cavalryroad,lahore cantt,pakistan.سازمان اصلی تایید شده: 0 موسسات و مراکز خارج از کشور shamila yasir gynae unit ii, fatima memorial hospital, lahore, pakistan.سازمان اصلی تایید شده: 0 موسسات و مراکز خارج از کشور

non–hodgkin lymphoma (nhl) causes many deaths worldwide with increasing incidence. non-hodgkin's lymphoma (nhl) may involve the gynecologic tract, and the ovary to be one of the commoner anatomic sites as reported. ovarian involvement by nhl is usually secondary, occurring as a part of systemic disease. the diagnosis is often made incidentally while investigating for gynecological symptoms. we ...

Journal: :Seminars in oncology 2009
Ching-Hon Pui Eckhard Thiel

Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching 90% in children and 50% in adults who are receiving contemporary risk-directed treatment protocols. Current efforts focus not only on further improving cure rate but also on patient quality of life. Hence, all protocols decrease or limit the use of cranial irradiation as central nervous system (CNS)-directed therapy, even ...

Journal: :Journal of Korean Medical Science 2002
Chul Won Choi Chang Won Paek Jae Hong Seo Byung Soo Kim Sang Won Shin Yeul Hong Kim Jun Suk Kim

The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C), and cisplatin, has been shown to be active against refractory or relapsed non-Hodgkin's lymphoma (NHL) in therapeutic trials. We undertook this study to determine whether this regimen would be effective and tolerable in Korean patients. A total of 40 patients ...

Journal: :Blood 1994
C Gisselbrecht D Maraninchi J L Pico N Milpied B Coiffier M Divine P Tiberghien A Bosly H Tilly O Boulat

A phase II study was undertaken to assess whether continuous infusion of high-dose recombinant interleukin-2 (rIL-2) alone was active against different histologic subtypes of heavily pretreated lymphoma. Sixty one lymphomas were included in the study. rIL-2 (Roussel UCLAF, Romainville, France) was administered by continuous infusion at 20 x 10(6) IU/m2 for three cycles of 5 days, 4 days, and 3 ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید